In-situ construction of amorphous/crystalline contact Bi2S3/Bi4O7 heterostructures for enhanced visible-light photocatalysis

Feihu Mu,Benlin Dai,Wei Zhao,Xiaofan Yang,Xiaolong Zhao,Xujing Guo

DOI: https://doi.org/10.1016/j.cclet.2020.12.016

IF: 9.1

2021-08-01

Chinese Chemical Letters

Abstract:Constructing a heterojunction photocatalyst is a significant method to enhance photocatalytic activity because it can promote the separation of photogenerated carriers. Herein, amorphous/crystalline contact Bi2S3/Bi4O7 heterostructure was successfully synthesized by in-situ sulfidation of Bi4O7. The amorphous Bi2S3 is diffused on the surface of Bi4O7 rod, enhancing the visible light response and improving the transport of photogenerated carriers. Various characterizations confirm that the rapid separation of photogenerated carriers leads to increased photocatalytic performance. The optimized Bi2S3/Bi4O7 heterostructure photocatalyst (BiS-0.15) exhibits the highest Cr(VI) reduction (0.01350 min−1) and RhB oxidation (0.08011 min−1) activity, which is much higher than that of pure Bi4O7 and Bi2S3/Bi4O7 mixture under visible light irradiation. This work provides new insights into the construction of efficient novel photocatalysts.

chemistry, multidisciplinary

What problem does this paper attempt to address?

The paper primarily explores the role of soluble urokinase-type plasminogen activator receptor (suPAR) in trauma patients and its relationship with inflammatory response and prognosis.

The research background is that trauma is one of the leading causes of death worldwide, especially among young people. Trauma can trigger a systemic inflammatory response, which is associated with the risk of late mortality in patients. As an immune activation marker, suPAR has certain predictive value in critically ill patients. However, the dynamic changes in suPAR levels in trauma patients and its relationship with immune response and outcomes remain unclear.

The research methods included analyzing plasma samples from 69 adult trauma patients, collected upon their arrival at the emergency room and over several days thereafter. Researchers measured the levels of suPAR and other inflammatory cytokines in the samples and analyzed the relationship between these indicators and the severity of the patients' injuries and their survival status.

The main conclusions are as follows:
1. Initial suPAR levels were higher in non-survivors than in survivors, but its value in predicting mortality was low.
2. suPAR levels increased over time, and this increase was associated with early cytokine levels.
3. Although suPAR levels were somewhat associated with mortality, it could not reliably distinguish between early and late deaths as a predictive marker.

In summary, although suPAR showed certain trends of change in trauma patients and was associated with inflammatory response, its ability to predict mortality as a single marker is limited. This suggests that in clinical practice, suPAR may need to be combined with other biomarkers to improve its predictive value.